Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.
- 1 March 1990
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 8 (3), 556-562
- https://doi.org/10.1200/jco.1990.8.3.556
Abstract
The purpose of this study was to determine which factors were associated with an increased risk of thrombo-hemorrhagic complications in a historical cohort of 100 consecutive and unselected patients with essential thrombocythemia (ET) in whom busulfan treatment was given when platelets were more than 1,000 x 10(9)/L and/or a major thrombotic or hemorrhagic event occurred. The incidence of major hemorrhagic complications was very low (0.33%/person-time at risk [pt-yr]) in comparison with that of thrombotic episodes (6.6%/pt-yr). In an adequate and appropriate control historical group of 200 patients, no severe hemorrhages were recorded and the incidence of thrombotic events was 1.2% pt-yr. Thus, the analysis of risk factors was restricted to this latter group of events. Age, a previous thrombotic event, and long duration of thrombocytosis were identified as major risk factors for thrombosis, while smoking, diabetes mellitus, hyperlipidemia, and hypertension did not influence the rate of thrombotic episodes.This publication has 15 references indexed in Scilit:
- Primary Thrombocythaemia in ChildhoodScandinavian Journal of Haematology, 2009
- The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: An analysis of 129 casesAmerican Journal of Hematology, 1985
- Acute Thrombotic Complications of Myeloproliferative Disorders in Young AdultsAmerican Journal of Clinical Pathology, 1985
- Erythromelalgia Caused by Platelet-Mediated Arteriolar Inflammation and Thrombosis in ThrombocythemiaAnnals of Internal Medicine, 1985
- 'Benign' monoclonal gammopathy. A misnomer?JAMA, 1984
- Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and functionEuropean Journal of Cancer and Clinical Oncology, 1983
- Neurologic Manifestations of Essential ThrombocythemiaAnnals of Internal Medicine, 1983
- ESSENTIAL THROMBOCYTHEMIA - RESPONSE DURING 1ST YEAR OF THERAPY WITH MELPHALAN AND RADIOACTIVE PHOSPHORUS - A POLYCYTHEMIA-VERA STUDY-GROUP REPORT1982
- Uncontrolled thrombocytosis in chronic myeloproliferative disordersBritish Journal of Haematology, 1982
- Essential thrombocythemia in a child: Platelet ultrastructure and functionAmerican Journal of Hematology, 1980